← boothcheck

Is CNO overvalued?

boothcheck doesn't label CNO overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-09-07T04:18:58.441Z, anchored at $56.75, CNO is priced for growth of +16.4%. Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode. The report narrative was composed 2026-07-25. The more the price assumes beyond what CNO Financial Group, Inc. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from CNO Financial Group, Inc.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed July 25, 2026.

Implied growth+16.4%
For about
Held margin (input)
Margin today
Price vs asset value1.61x
Price vs earnings power1.80x
Read the full CNO report →
Get boothcheck's read on what CNO's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.